Multiple Sclerosis, Relapsing-Remitting

Inclusion Criteria

- Female and Male patients aged 18 and more;
 - Confirmed diagnosis of RRMS according to the MacDonald or Poser criteria;
 - First indication for Betaferon treatment (as described in Summary of Product Characteristics (SmPC));
 - No relapse of multiple sclerosis (MS) in the last two months before the inclusion;
 - Walking patients having an Expanded Disability Status Scale (EDSS) score between > 1 and </= 4 at the inclusion visit;
 - Female of child-bearing potential must agree to practice adequate contraception methods over all the duration of the study;
 - Patient can follow all the study and comply with all procedures of the trial protocol
 - Laboratory evaluations (i.e. evaluation of hepatic enzymes gammaGT, full blood count and differential white blood cell [WBC]) must be available and the results must be normal;
 - Written informed consent.

Exclusion Criteria

- Any contraindication to Betaferon as described in the SmPC of the product;
 - Patient with a previously orthopaedic surgical intervention within the past year of the inclusion;
 - Patient previously included in this study;
 - Patient previously treated within the past 3 months with Rebif, Avonex or Copaxone;
 - Patient previously treated within the past 12 months with Betaferon;
 - Participation in any clinical trial within the past 30 days involving the investigational drug intake.